drugset / Trial / NCT06640920
A Study to Investigate Efficacy and Safety of NSI-8226 in Healthy Participants
RandomizedParallel-groupQuadruple-blindTreatment
Summary
A Phase 1 Randomized, Double-Blind Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Bioavailability of NSI-8226 in Healthy Participants.
Timeline
- Start
- 2024-04-29
- Primary completion
- 2024-10-29
- Completion
- 2024-10-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Solrikitug | Monoclonal antibody | — | Intravenous |
Indications
No indication recorded.